Fagron’s Share Buy-Back Program: Key Update
Fagron is making significant progress with its share buy-back program, which is aimed at boosting shareholder value through the strategic repurchase of its own shares. In just a week, the company has successfully acquired a notable number of shares, demonstrating its commitment to long-term growth and stability.
Recent Share Acquisitions
From 26 August 2024 to 30 August 2024, Fagron purchased 37,000 shares at an average price of €18.99. This initiative represents a total investment of approximately €1,357,476.41, highlighting Fagron's proactive strategy in managing its equity.
These purchases are part of Fagron's ongoing buy-back program, which aims to meet obligations related to its long-term incentive schemes. Announced earlier this month, the program's goal is to repurchase up to 150,000 shares, showcasing a strong strategy to bolster the company’s performance and instill investor confidence.
Total Shares Acquired
Currently, Fagron has repurchased a total of 71,500 shares. This substantial figure reflects the company's commitment to enhancing its stock value while fulfilling its obligations to various incentive plans.
Future Outlook: Financial Updates
Looking forward, Fagron has planned important financial updates, with the next trading update for Q3 2024 scheduled for 10 October 2024. This commitment to transparency ensures that investors stay informed about the company’s performance and financial health.
Results Publication
Results and trading updates are consistently published at 7:00 AM CET, enabling stakeholders to remain informed about the company’s developments. This dedication to regular reporting underscores Fagron's commitment to maintaining clear and open lines of communication with its investors.
Understanding Fagron’s Mission
Fagron is a leader in pharmaceutical compounding, actively working to provide personalized medications to healthcare facilities, including hospitals and pharmacies, in over 30 countries. Its strategic emphasis on enhancing patient care through customized solutions distinguishes it within the pharmaceutical sector.
Company Overview
Fagron NV, a respected Belgian company, is headquartered in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. The management of its operational activities is conducted through its Dutch subsidiary, Fagron BV, located in Rotterdam. This international footprint highlights Fagron’s significant role in the global healthcare landscape.
Frequently Asked Questions
What is the purpose of Fagron's share buy-back program?
The share buy-back program aims to enhance shareholder value by repurchasing shares, reflecting the company's commitment to long-term growth.
How many shares has Fagron purchased in total?
To date, Fagron has repurchased a total of 71,500 shares under its buy-back program.
When will the next financial update be published?
The next financial update is set for 10 October 2024, with results released at 7:00 AM CET.
What is Fagron's area of expertise?
Fagron specializes in pharmaceutical compounding, focusing on personalized medicine for hospitals and pharmacies worldwide.
Where is Fagron's headquarters located?
Fagron NV's headquarters is in Nazareth, Belgium, with operational management based in Rotterdam, the Netherlands.
